H. Ben-hur et al., Soluble low-molecular-mass tumor-associated proteins promote the suppression of mammary tumors by cyclophosphamide, INT J ONCOL, 19(2), 2001, pp. 407-411
This study examined whether the soluble tumor-associated-antigens (TAA), of
66 kDa and 51 kDa, could promote suppression by anticancer drugs of chemic
ally-induced mammary tumorigenesis. Dimethylbenzanthracene (DMBA, 10 mg/rat
, twice) was used to induce mammary tumors. Then, for nine more weeks, the
preparation of TAA and cyclophosphamide (CPA), alone or in combination with
TAA, were administered in weekly doses. Twenty weeks after DMBA exposure,
the mammary tumor yield was 2.4, 2.8 and 2.9 in the experimental groups com
pared to 3.5 in the controls. Seventy-five percent of the rats in the contr
ol group, but only 37% of TAA, 50% of the CPA, and 30% of the CPA and TAA t
reated animals had malignant tumors. In the experimental groups, 6.5%, 25%
and 38%, respectively, of the tumors regressed, compared to 3% in controls.
In the groups receiving CPA or TAA, regression was observed in the fifth w
eek of treatment, and in the group receiving combined treatment, already in
the first week. The size of the tumors in control rats increased during th
e last 10 weeks 3.6 times, in the CPA treated rats 1.15 times, but in those
receiving CPA plus TAA it decreased by 0.7 times. The results of our exper
iment demonstrated that TAA have distinct tumor-suppressive properties, and
can enhance the anticancer effects of CPA.